circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-23. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
== Mechanism of action == Methylnaltrexone is a peripheral acting mu-opioid receptor antagonist, and does not cross the blood brain barrier. Methylnaltrexone has restricted access through the blood brain barrier because it is a quaternary amine, which carries a positive charge when in a solution. This positive charge increases polarity and decreases lipid solubility when compared to traditional opioid agonists used for pain treatment. The peripheral action of methylnaltrexone makes it effective for decreasing the constipating effects of opioids, without interfering with the analgesic effects (of opioids) on the central nervous system. This is the primary characteristic that makes methylnaltrexone behave differently than naltrexone. Furthermore, as methylnaltrexone cannot cross the blood–brain barrier, it does not reverse the pain-killing properties of opioid agonists or cause withdrawal symptoms, but since a small portion of analgesia comes from the peripheral opioid receptors, it can increase pain from inflammatory conditions such as arthritis.
=== Distribution === The apparent oral volume of distribution (VSS/F) at steady state of (R)-bicalutamide with oral administration of a single 5 to 80 mg dose of (R)-bicalutamide in a novel solid dispersion with a polymeric matrix of hydroxypropyl methylcellulose phthalate (HP55S) (also known as (R)-bicalutamide/HP55S) ranges from 22.53 ± 3.71 L to 25.38 ± 2.69 L. Bicalutamide is highly protein-bound (96.1% for racemic bicalutamide, 99.6% for (R)-bicalutamide), mainly to albumin. It has negligible affinity for SHBG and no affinity for corticosteroid-binding globulin. The tissue distribution of bicalutamide is not well-characterized. However, it has been reported that distribution studies with bicalutamide have shown that preferential (i.e., tissue-selective) accumulation in anabolic (e.g., muscle) tissues does not occur. There are no available data on hepatic bicalutamide concentrations in humans, but a rat study found that oral bicalutamide treatment resulted in 4-fold higher concentrations of the drug in the liver relative to plasma (a common finding with orally administered drugs, due to transfer through the hepatic portal system prior to reaching circulation). In men receiving 150 mg/day bicalutamide, concentrations of (R)-bicalutamide in semen were 4.9 μg/mL (11 μmol/L), and the amount of the drug that could potentially be delivered to a female partner during sexual intercourse is regarded as low (estimated at 0.3 μg/kg) and below the amount that is required to induce changes in the offspring of laboratory animals.
The experimental determination of pKa values is commonly performed by means of titrations, in a medium of high ionic strength and at constant temperature. A typical procedure would be as follows. A solution of the compound in the medium is acidified with a strong acid to the point where the compound is fully protonated. The solution is then titrated with a strong base until all the protons have been removed. At each point in the titration pH is measured using a glass electrode and a pH meter. The equilibrium constants are found by fitting calculated pH values to the observed values, using the method of least squares. The total volume of added strong base should be small compared to the initial volume of titrand solution in order to keep the ionic strength nearly constant. This will ensure that pKa remains invariant during the titration. A calculated titration curve for oxalic acid is shown at the right. Oxalic acid has pKa values of 1.27 and 4.27. Therefore, the buffer regions will be centered at about pH 1.3 and pH 4.3. The buffer regions carry the information necessary to get the pKa values as the concentrations of acid and conjugate base change along a buffer region. Between the two buffer regions there is an end-point, or equivalence point, at about pH 3. This end-point is not sharp and is typical of a diprotic acid whose buffer regions overlap by a small amount: pKa2 − pKa1 is about three in this example. (If the difference in pK values were about two or less, the end-point would not be noticeable.) The second end-point begins at about pH 6.3 and is sharp.
Sources: en.wikipedia.org
=== Colon Treaty of Peace and Friendship === On August 26, 1876, the Grand Lodge of Colon in Santiago de Cuba declared itself entirely independent as a sovereign Masonic Body with its own full and unlimited powers over its own subordinate lodges. Under their auspices, the Grand Lodge of Colon possessed 36 lodges and 8,000 members. On November 24, 1876, the Grand Lodge of Colon and the Supreme Council of Colon signed the Tratado de Paz y Amistad (English: Treaty of Peace and Friendship). This treaty was based in the agreements of the Lausanne Congress. It degraded the superior prestige of the higher degrees, eliminated authoritarian positions at the Supreme Council, ejected the Spanish aristocracy from holding undue power, and erased the mystical positions. The Supreme Council of Colon recognized the Grand Lodge of Colon as "regular and correct," and also recognized their authority over the three degrees of the Blue Lodge. The Grand Lodge recognized the Supreme Council as the authority over the 4th to 33rd degrees.
They are better used with a larger wound such as ulcers or donor sites. Hydro-fiber dressings: these dressings are similar to alginate dressings when it comes to absorbing characteristics, but they do not affect hemostasis. They are composed in sheets which contain polymer carboxymethylcellulose and can be cut according to wound size and severity. However, when using these dressings, a secondary dressing is almost always required. Transparent film dressings: this specific type of dressing is more like a plastic covering for the wound. It allows oxygen to reach it and help heal but does not absorb any fluids. Transparent film dressings are used primarily on dry wounds. Hydrogel dressings: this type of dressing is more directed towards infected areas and those in need of a moist environment to heal properly. It helps promote the body's own natural functions of removing necrotic tissue. It is advised not to be used on dry wounds. Hydrocolloid dressings: unlike transparent film dressings, hydrocolloid dressings do not allow oxygen to reach the wound. It is a wet-to-dry technique but is not recommended for infected areas. This type of dressing can last up to 7 days with a close eye and must be removed with care. Biologically based dressings: Integra LifeSciences’ artificial skin is placed on a wound where burned or scarred skin has been removed. Composed of two-layers, an under layer made of collagen from cows and glycosaminoglycan from shark cartilage, and an outer silicone layer, the membrane provides scaffolding to regrow a new layer of dermis.
Kief is a powder, rich in trichomes, that can be sifted from the leaves, flowers and fruits of cannabis plants and either consumed in powder form or compressed to produce cakes of hashish. The term derives from colloquial Arabic كيف kēf/kīf, meaning pleasure.
Severity of injury found on imaging will determine whether the surgeon takes an operative or close observational approach. Diagnostic peritoneal lavage (DPL) has become largely obsolete with the advances in MDCT, with use limited to centers without access to CT to guide requirement for urgent transfer for operation.
Sources: en.wikipedia.org
==== Muscle ==== Glycogen storage diseases that involve skeletal muscle typically have exercise-induced (dynamic) symptoms, such as premature muscle fatigue, rather than fixed weakness (static) symptoms. Differential diagnoses for glycogen storage diseases that involve fixed muscle weakness, particularly of the proximal muscles, would be an inflammatory myopathy or a limb-girdle muscular dystrophy. For those with exercise intolerance and/or proximal muscle weakness, the endocrinopathies should be considered. The timing of the symptoms of exercise intolerance, such as muscle fatigue and cramping, is important in order to help distinguish it from other metabolic myopathies such as fatty acid metabolism disorders. Problems originating within the circulatory system, rather than the muscle itself, can produce exercise-induced muscle fatigue, pain and cramping that alleviates with rest, resulting from inadequate blood flow (ischemia) to the muscles. Ischemia that often produces symptoms in the leg muscles includes intermittent claudication, popliteal artery entrapment syndrome, and chronic venous insufficiency. Diseases disrupting the neuromuscular junction can cause abnormal muscle fatigue, such as myasthenia gravis, an autoimmune disease. Similar, are Lambert–Eaton myasthenic syndrome (autoimmune) and the congenital myasthenic syndromes (genetic). Diseases can disrupt glycogen metabolism secondary to the primary disease.
Measurements over 10 pCi/L warrant only another short-term test so that abatement measures are not unduly delayed. The EPA has advised purchasers of real estate to delay or decline a purchase if the seller has not successfully abated radon to 4 pCi/L or less. Because the half-life of radon is only 3.8 days, removing or isolating the source will greatly reduce the hazard within a few weeks. Another method of reducing radon levels is to modify the building's ventilation. Generally, the indoor radon concentrations increase as ventilation rates decrease. In a well-ventilated place, the radon concentration tends to align with outdoor values (typically 10 Bq/m3 (0.27 pCi/L), ranging from 1 to 100 Bq/m3 (0.027 to 2.703 pCi/L). The four principal ways of reducing the amount of radon accumulating in a house are:
=== Angiogenesis === The formation of new blood vessels is essential for tumor survival and expansion. Intracrines like VEGF and angiogenin regulate angiogenesis within tumor cells and surrounding endothelial cells. Inhibiting intracrine trafficking of angiogenin to the nucleus has been shown to blunt cancer cell proliferation, making this an emerging therapeutic target.
In late 1918, Poles hoping for a sovereign Poland started serious preparations for an uprising after Wilhelm II's abdication on 9 November 1918, which marked the end of the German Empire. The monarchy was replaced by the Weimar Republic. The uprising broke out on 27 December 1918 in Poznań, after a patriotic speech by Ignacy Paderewski, the famous pianist, who would become the Polish prime minister in 1919, with 2,000 men serving in the Guard and Security Service rising up in the city. The insurrectionist forces consisted of members of the Polish Military Organization, who formed the Straż Obywatelska (Citizen's Guard), later renamed as Straż Ludowa (People's Guard), which included many volunteers, who were mainly veterans of World War I. The first contingent to reach the Bazar Hotel, from where the uprising was initiated, was a 100-strong force from wildecka kompania Straży Ludowej (Wilda's People's Guard) led by Antoni Wysocki. The ruling body was the Naczelna Rada Ludowa (Supreme People's Council). Initially, the members of the council, including Captain Stanisław Taczak and General Józef Dowbor-Muśnicki were against the uprising, but they changed their minds in support of the insurrection on 9 January 1919. The timing was advantageous for the insurrectionists since between late 1918 and early 1919, internal conflict had weakened Germany, and many of its soldiers and sailors engaged in mutinous actions against the state. Demoralized by the signing of the armistice on 11 November 1918, the new German government was further embroiled in subduing the German Revolution.
DCPIP can also be used as an indicator for vitamin C. If vitamin C, which is a good reducing agent, is present, the blue dye, which turns pink in acidic conditions, is reduced to a colorless compound by ascorbic acid. This reaction is a redox reaction: vitamin C (ascorbic acid) is oxidized to dehydroascorbic acid, and DCPIP is reduced to the colorless compound DCPIPH2
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.